SLRX:NSD-Salarius Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.91

Change

-0.06 (-6.19)%

Market Cap

N/A

Volume

0.03M

Analyst Target

USD 4.43
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.99 (+1.78%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

+11.55 (+1.73%)

USD 76.39B
ARGX argenx NV ADR

+9.23 (+1.53%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

+11.35 (+4.69%)

USD 31.94B
ONC BeiGene, Ltd.

+5.88 (+2.27%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.25 (+0.76%)

USD 18.65B
SMMT Summit Therapeutics PLC

-0.66 (-3.17%)

USD 17.01B
UTHR United Therapeutics Corporatio..

+15.70 (+5.11%)

USD 14.37B
INCY Incyte Corporation

-5.85 (-8.62%)

USD 14.22B
MRNA Moderna Inc

+0.09 (+0.26%)

USD 13.74B

ETFs Containing SLRX

SRET Global X SuperDividend® .. 3.50 % 0.59 %

+0.09 (+0.42%)

USD 0.19B
REM iShares Mortgage Real Est.. 3.23 % 0.48 %

+0.14 (+0.42%)

USD 0.64B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -50.54% 10% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.54% 10% F 7% C-
Trailing 12 Months  
Capital Gain -81.17% 18% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.17% 18% F 7% C-
Trailing 5 Years  
Capital Gain -99.31% 7% C- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.31% 7% C- 2% F
Average Annual (5 Year Horizon)  
Capital Gain 100.91% 84% B 92% A
Dividend Return 100.91% 84% B 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 892.79% 13% F 5% F
Risk Adjusted Return 11.30% 62% D 43% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.